

Reporting of Sociodemographic and Clinical Characteristics in US-Based Randomized Clinical Trials of Deprescribing Interventions for Older Adults

Short title: Reporting Sociodemographic and Clinical Characteristics in US Deprescribing Trials for Older Adults

Authors and Affiliations

Katharina Tabea Jungo, PhD ^{1,2}

Jeanne Wildisen, MMed ²

Julie C. Lauffenburger, PharmD, PhD ¹

Donovan T. Maust, MD, MS ^{3,4}

Alexander Chaitoff, MD, MPH ^{3,5}

¹ Center for Healthcare Delivery Sciences (C4HDS), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

² Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.

³ Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI.

⁴ Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor, MI.

⁵ Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI.

Corresponding author

Katharina Jungo, Institute of Primary Healthcare (BIHAM), University of Bern, Switzerland / Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St, Boston, MA 02120

katharina.jungo@unibe.ch

Table 1. Patient sociodemographic and clinical characteristics across randomized clinical trials (RCTs)

Author (publication year, sample size)	Setting	Mean age (SD)	% Female	% non-White	% Hispanic ⁱ	Pragmatic recruitment (yes/no) ^{viii}	Older adults with cognitive impairment		Education status reported (yes/no)	Chronic conditions		
							Enrolment of patients with cognitive impairment (yes/no)	% with cognitive impairment		Mean number	Types reported	Comorbidity indices used (yes/no)
Bayliss et al. (2022, 3012) ¹	Primary care clinics, Kaiser Permanente Colorado	80 (7.4)	56	22	NR	yes	yes	100	no	8.6	no	no
Black et al. (2006, 1099) ²	11 clinical centers (unspecified)	73 (5.7)	100 ^v	2.7	NR	no	no	-	no	NR	no	no
Bridges-Parlet et al. (1997, 36) ³	5 nursing homes	83.0 (NA)	80.8	NR	NR	no	yes	100	no	NR	no	no
Campbell et al. (2021, 552) ⁴	Primary care clinics, Eskenazi Health	72.1 (6.4)	80	58	NR	yes	yes	16	no	NR	yes	no
Cohens-Mansfield et al. (1999, 58) ⁵	1 nursing home	86 (NA)	74.1	NR	NR	no	yes	NR	yes	6	no	no
Dawson et al. (1999, 45) ⁶	54 centers (unspecified)	63.8 (NA)	13.3	11	NR	no	no	-	no	NR	partial ⁱⁱⁱ	no
Dawson-Hughes et al. (2000, 295) ⁷	Ambulatory care (unspecified)	73.5 (NA)	57	NR	NR	no	no	-	no	NR	no	no
Devanand et al. (2011, 20) ⁸	Memory disorders clinic & behavioral neurology practice	75 (8)	57	43	NR	no	yes	100	yes	NR	no	no
Devanand et al. (2012, 110) ⁹	Memory clinics, geriatric psychiatry clinics, VA clinics	80 (7.6)	59	28	NR	no	yes	100	yes	NR	no	no
Espeland et al. (1999, 975)	Communities near 4 academic medical institutions	NR	48	24	NR	no	no	-	no	NR	no	no
Gallagher et al. (2002, 489) ¹⁰	Not specified	72 (0.3)	100 ^v	4	NR	no	no	-	no	NR	no	no
Gaudig et al. (2011, 978) ¹¹	Multicenter (unspecified)	75 (1.2)	58	9	NR	no	yes	100	no	NR	no	no
Hanlon et al. (1996, 208) ¹²	General medicine clinic (VA)	70 (NA)	1.0	23.1	NR	no	yes	NR	yes	9.1	no	no
Herrinton et al. (2023, 2470) ¹³	Kaiser Permanente Northern California	80 (NA)	51	36	NR	yes	yes	NR	no	NR	no	yes
Kuntz et al. (2019, 150) ¹⁴	Kaiser Permanente Northwest	70 (6)	66	5	NR	yes	no	-	no	NR	yes	yes (no summary score provided)
Kutner et al. (2015, 381) ¹⁵	Multicenter (unspecified)	74 (11.6)	45	17	4	no	yes	22	yes	NR	partial ⁱⁱⁱ	yes
Moga et al. (2017, 50) ¹⁶	Patients enrolled in Alzheimer's Disease Center cohort, University of Kentucky	77.7 (6.6)	70	10	NR	no	yes	34	yes	NR	no	no
Moo et al. (2021, 62) ¹⁷	Multicenter (VA)	77.6 (NA)	2	13	0	no	yes	NR	no	NR	no	no
Mott et al. (2003, 80) ¹⁸	Unspecified	75.6 (NA)	78.7	1.3	1.5	no	no	-	yes	NR	no	no
Navy et al. (2018, 314) ¹⁹	Kaiser Permanente Colorado	73 (NA)	64.2	14.8	6.9	yes	yes	5.1	yes	NR	yes	yes
O'Brien et al. (2001, 25) ²⁰	Outpatient pulmonary department (VA)	67 (1.9)	0	NR	NR	no	no	-	no	NR	no	no
Rice et al. (2000, 38) ²¹	Unspecified	69.9 (NA)	0	NR	NR	no	no	-	no	NR	no	no
Tabloski et al. (1998, 20) ²²	Unspecified	77.5 (7.9)	100 ^v	NR	NR	no	no	-	no	NR	no	no
Tariot et al. (1999, 47) ²³	Unspecified	86 (6.4)	80	2	NR	no	yes	100	yes	NR	no	no
Tse et al. (2008, 11) ²⁴	Academic nursing home	82.8 (NA)	36.3	NR	NR	no	yes	100	no	NR	no	no
Vasilevskis et al. (2023, 372) ²⁵	Vanderbilt University Medical Center	76.2 (10.7)	62	16	NR	yes	yes	24.4	yes	NR	no	yes
Vaughan (2022, n/a) ²⁶	Emergency department (ED)	NR	NR	NR	NR	yes	no	-	no	NR	no	no
Weber et al. (2005, 620) ²⁷	Geisinger Health System	77 (NA)	79.3	NR	NR	yes	yes	2	no	8.6	no	no
Overall^{vii}	-	Median (IQR) = 77.7 (73-80), Mean(SD) = 76.9 (3.7)	Median (IQR) = 56 (51-66), Mean (SD) = 61.4 (20.0)	Median (IQR) = 22 (9-36), Mean = 22.0 (14.6)	Median (IQR) = 4.0 (4-7), Mean (SD) = 4.5 (2.5)	8 RCTs used pragmatic identification without individual participant consent	Included by 17 RCTs	Median (IQR)= 16 (2-22), Mean (SD) = 13.5 (10.3)^e	Reported by 10 RCTs	Median (IQR) = 8.6 (8.6-8.6), Mean (SD) = 8.6 (0.5)	Reported by 5 RCTs	Reported by 5 RCTs

Table 1 (continued). Patient sociodemographic and clinical characteristics across randomized clinical trials (RCTs)

Author (publication year, sample size)	Medications		Living conditions reported (yes/no)	Frailty status reported (yes/no)	Language		Quality of life reported (yes/no)	Health services use reported (yes/no)	Income reported (yes/no)
	Mean number	Types reported (yes/no)			Reported (yes/no)	Older adults with insufficient English proficiency excluded (yes/no)			
Bayliss et al. (2022, 3012) ¹	7	no	no	no	no	no	no	no	no
Black et al. (2006, 1099) ²	NR	no	no	no	no	no	no	no	no
Bridges-Parlet et al. (1997, 36) ³	NR	no	yes	no	no	no	no	no	no
Campbell et al. (2021, 552) ⁴	NR	no	no	no	no	no	no	no	no
Cohens-Mansfield et al (1999, 58) ⁵	NR	partial ^{iv}	yes	no	no	no	no	no	no
Dawson et al. (1999, 45) ⁶	NR	no	no	no	no	no	no	no	no
Dawson-Hughes et al. (2000, 295) ⁷	NR	no	no	no	no	no	no	no	no
Devanand et al. (2011, 20) ⁸	NR	no	no	no	no	no	no	no	no
Devanand et al. (2012, 110) ⁹	NR	partial ^{iv}	yes	no	no	no	no	no	no
Espeland et al. (1999, 975)	NR	partial ^{iv}	no	no	no	no	no	no	no
Gallagher et al. (2002, 489) ¹⁰	NR	no	no	no	no	no	no	no	no
Gaudig et al. (2011, 978) ¹¹	NR	no	no	no	no	no	no	no	no
Hanlon et al. (1996, 208) ¹²	7.9	no	no	no	no	no	yes	no	no
Herrinton et al. (2023, 2470) ¹³	NR ²	no	no	no	no	yes	no	yes	no
Kuntz et al. (2019, 150) ¹⁴	NR	partial ^{iv}	no	no	no	no	no	yes	no
Kutner et al. (2015, 381) ¹⁵	NR	partial ^{iv}	no	no	yes	yes	yes	no	no
Moga et al. (2017, 50) ¹⁶	NR	partial ^{iv}	no	no	no	no	yes	no	no
Moo et al. (2021, 62) ¹⁷	NR	no	no	no	no	no	no	no	no
Mott et al. (2003, 80) ¹⁸	NR	no	no	no	no	yes	no	no	no
Navy et al. (2018, 314) ¹⁹	NR	no	no	no	no	yes	no	no	yes
O'Brien et al. (2001, 25) ²⁰	NR	no	no	no	no	no	yes	no	no
Rice et al. (2000, 38) ²¹	NR	partial ^{iv}	no	no	no	no	no	no	no
Tabloski et al. (1998, 20) ²²	NR	partial ^{iv}	yes	no	no	no	no	no	no
Tariot et al. (1999, 47) ²³	NR	no	no	yes	no	no	no	no	no
Tse et al. (2008, 11) ²⁴	NR	no	yes	no	no	no	no	no	no
Vasilevskis et al. (2023, 372) ²⁵	NR	no	yes	no	no	yes	no	yes	no
Vaughan (2022, n/a) ²⁶	NR	no	no	no	no	no	no	no	no
Weber et al. (2005, 620) ²⁷	7.7	partial ^{iv}	yes	no	no	no	no	no	no
Overall^{viii}	Median (IQR) = 7 (7-7), Mean (SD) = 7.2 (0.4)	Partially^v reported by 9 RCTs	Reported by 7 RCTs	Reported by 1 RCT	Reported by 1 RCT	Excluded from 5 RCTs	Reported by 4 RCTs	Reported by 3 RCTs	Reported by 1 RCT

NA=not available, NR=not reported, RCT=randomized clinical trials, SD=standard deviation, VA=Veterans Affairs ⁱ If ethnicity was reported separately from race. ⁱⁱ Reported as categories. ⁱⁱⁱ Only select chronic conditions of interest reported. ^{iv} Only select medication classes of interest reported. ^v Female participants only as specified by the inclusion criteria. ^{vi} Excluding the trials that exclusively recruited participants with cognitive impairment. ^{vii} Means and medians weighted for sample sizes of RCTs. ^{viii} Using routinely collected data to identify patients and no individual patient consent for study enrollment. ⁱ We identified RCTs conducted in the US from a recently published systematic review on the effect of deprescribing in adults aged ≥65 years, which included published studies and grey literature indexed until April 2024 and updated a previous systematic review ^{28,29}

References

1. Bayliss EA, Shetterly SM, Drace ML, Norton JD, Maiyani M, Gleason KS, Sawyer JK, Weffald LA, Green AR, Reeve E, Maciejewski ML, Sheehan OC, Wolff JL, Kraus C, Boyd CM. Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians: The OPTIMIZE Pragmatic Cluster Randomized Trial. *JAMA Intern Med.* May 1 2022;182(5):534-542. doi:10.1001/jamainternmed.2022.0502
2. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *Jama.* Dec 27 2006;296(24):2927-38. doi:10.1001/jama.296.24.2927
3. Bridges-Parlet S, Knopman D, Steffes S. Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study. *J Geriatr Psychiatry Neurol.* Jul 1997;10(3):119-26. doi:10.1177/089198879701000306
4. Campbell NL, Holden RJ, Tang Q, Boustani MA, Teal E, Hillstrom J, Tu W, Clark DO, Callahan CM. Multicomponent behavioral intervention to reduce exposure to anticholinergics in primary care older adults. *J Am Geriatr Soc.* Jun 2021;69(6):1490-1499. doi:10.1111/jgs.17121
5. Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Woosley R. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. *Archives of internal medicine.* Aug 9-23 1999;159(15):1733-40. doi:10.1001/archinte.159.15.1733
6. Dawson DL, DeMaioibus CA, Hagino RT, Light JT, Bradley DV, Jr., Britt KE, Charles BE. The effect of withdrawal of drugs treating intermittent claudication. *Am J Surg.* Aug 1999;178(2):141-6. doi:10.1016/s0002-9610(99)00147-6
7. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. *Am J Clin Nutr.* Sep 2000;72(3):745-50. doi:10.1093/ajcn/72.3.745
8. Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. *Int J Geriatr Psychiatry.* Sep 2011;26(9):937-43. doi:10.1002/gps.2630
9. Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B. Relapse risk after discontinuation of risperidone in Alzheimer's disease. *The New England journal of medicine.* Oct 18 2012;367(16):1497-507. doi:10.1056/NEJMoa1114058
10. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. *J Clin Endocrinol Metab.* Nov 2002;87(11):4914-23. doi:10.1210/jc.2002-020727
11. Gaudig M, Richarz U, Han J, Van Baelen B, Schäuble B. Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. *Curr Alzheimer Res.* Nov 2011;8(7):771-80. doi:10.2174/156720511797633205
12. Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, Cowper PA, Landsman PB, Cohen HJ, Feussner JR. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. *Am J Med.* Apr 1996;100(4):428-37. doi:10.1016/s0002-9343(97)89519-8
13. Herrinton LJ, Lo K, Alavi M, Alexeeff SE, Butler KM, Chang C, Chang CC, Chu VL, Krishnaswami A, Deguzman LH, Prausnitz S, Mason MD, Draves M. Effectiveness of Bundled Hyperpolypharmacy Deprescribing Compared With Usual Care Among Older Adults: A Randomized Clinical Trial. *JAMA network open.* Jul 3 2023;6(7):e2322505. doi:10.1001/jamanetworkopen.2023.22505
14. Kuntz JL, Kouch L, Christian D, Hu W, Peterson PL. Patient Education and Pharmacist Consultation Influence on Nonbenzodiazepine Sedative Medication Deprescribing Success for Older Adults. *Perm J.* 2019;23:18-161. doi:10.7812/tpp/18-161
15. Kutner JS, Blatchford PJ, Taylor DH, Jr., Ritchie CS, Bull JH, Fairclough DL, Hanson LC, LeBlanc TW, Samsa GP, Wolf S, Aziz NM, Currow DC, Ferrell B, Wagner-Johnston N, Zafar SY, Cleary JF, Dev S, Goode PS, Kamal AH, Kassner C, Kvale EA, McCallum JG, Ogunseitan AB, Pantilat SZ, Portenoy RK, Prince-Paul M, Sloan JA, Swetz KM, Von Gunten CF, Abernethy AP. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA Intern Med.* May 2015;175(5):691-700. doi:10.1001/jamainternmed.2015.0289
16. Moga DC, Abner EL, Rigsby DN, Eckmann L, Huffmyer M, Murphy RR, Coy BB, Jicha GA. Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden. *Alzheimers Res Ther.* May 23 2017;9(1):36. doi:10.1186/s13195-017-0263-9
17. Moo LR, Martinez E, Padala K, Dunay MA, Scali RR, Chen S, Thielke SM. Unexpected Findings During Double-blind Discontinuation of Acetylcholinesterase Inhibitor Medications. *Clinical therapeutics.* Jun 2021;43(6):942-952. doi:10.1016/j.clinthera.2021.05.010
18. Mott DA, Martin B, Breslow R, Michaels B, Kirchner J, Mahoney J, Margolis A. Impact of a medication therapy management intervention targeting medications associated with falling: Results of a pilot study. *J Am Pharm Assoc (2003).* Jan 2016;56(1):22-8. doi:10.1016/j.japh.2015.11.001
19. Navy HJ, Weffald L, Delate T, Patel RJ, Dugan JP. Clinical Pharmacist Intervention to Engage Older Adults in Reducing Use of Alprazolam. *Consult Pharm.* Dec 1 2018;33(12):711-722. doi:10.4140/TCP.n.2018.711.
20. O'Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M, Sherman C, Rounds S. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. *Am J Respir Crit Care Med.* Aug 1 2001;164(3):365-71. doi:10.1164/ajrccm.164.3.2002052
21. Rice KL, Rubins JB, Lebahn F, Parenti CM, Duane PG, Kuskowski M, Joseph AM, Niewoehner DE. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. *Am J Respir Crit Care Med.* Jul 2000;162(1):174-8. doi:10.1164/ajrccm.162.1.9909066
22. Tabloski PA, Cooke KM, Thoman EB. A procedure for withdrawal of sleep medication in elderly women who have been long-term users. *J Gerontol Nurs.* Sep 1998;24(9):20-8; quiz 50-1. doi:10.3928/0098-9134-19980901-10
23. Tariot PN, Jakimovich LJ, Erb R, Cox C, Lanning B, Irvine C, Podgorski CA. Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. *J Clin Psychiatry.* Oct 1999;60(10):684-9. doi:10.4088/jcp.v60n1007
24. Tse W, Frisina PG, Hålbjerg TD, Gracies JM, Liang L, Tarshish C, Lesser G, Neufeld R, Koller WC, Libow LS. The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism. *Journal of the American Medical Directors Association.* Nov 2008;9(9):670-5. doi:10.1016/j.jamda.2008.07.001
25. Vasilevskis EE, Shah AS, Hollingsworth EK, Shotwell MS, Kripalani S, Mixon AS, Simmons SF. Deprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial. *JAMA Intern Med.* Mar 1 2023;183(3):223-231. doi:10.1001/jamainternmed.2022.6545
26. Vaughan CP, Birmingham Z, Kelleher JL, McGwin G, Jasien CL, Hastings SN, Stevens MB, Morris I, Jackson GL. A cluster-randomized trial of two implementation strategies to deliver audit and feedback in the EQUIPPED medication safety program. *Acad Emerg Med.* Apr 2023;30(4):340-348. doi:10.1111/acem.14697
27. Weber V, White A, McIlvried R. An electronic medical record (EMR)-based intervention to reduce polypharmacy and falls in an ambulatory rural elderly population. *J Gen Intern Med.* Apr 2008;23(4):399-404. doi:10.1007/s11606-007-0482-z
28. Quek HW, Page A, Lee K, Lee G, Hawthorne D, Clifford R, Potter K, Etherton-Beer C. The effect of deprescribing interventions on mortality and health outcomes in older people: An updated systematic review and meta-analysis. *Br J Clin Pharmacol.* Oct 2024;90(10):2409-2482. doi:10.1111/bcp.16200
29. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. *Br J Clin Pharmacol.* Sep 2016;82(3):583-623. doi:10.1111/bcp.12975